Figure 2

hMSC decreased cytotoxic capacity of CD8⁺ T lymphocytes and NK cells in tumor-bearing mice.

(a) There was a significant increase in total number of splenocytes in tumor-bearing mice compared to mice from control group. The cytotoxic capacity of splenocytes derived from tumor-bearing mice was significantly lower than cytotoxic capacity of splenocytes derived from healthy animals. Combined results of 3 experiments with at least 9 animals per group (median ± s.e.m; *P < 0.05). (b) There was no significant difference in total number of CD8⁺ T lymphocytes in tumor-bearing mice compared to mice from control group. There was significant decrease in cytotoxic capacity of CD8⁺ T cells derived from spleens of tumor-bearing hMSC treated mice. Combined results of 3 experiments with at least 9 animals per group (median ± s.e.m.; *P < 0.05). (c) There was no significant difference in total number of CD3⁻NKp46⁺ NK cells in tumor-bearing mice compared to mice from control group. There was significant decrease in cytotoxic capacity of CD3⁻NKp46⁺ NK cells derived from spleens of tumor-bearing hMSC treated mice. Combined results of 3 experiments with at least 9 animals per group (median ± s.e.m.; *P < 0.05).